Sun, Feb 1, 2015, 7:55 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

CEL-SCI Corporation Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • yardbird09 yardbird09 Mar 1, 2011 4:53 PM Flag

    Geert may be on to something!!!!!!

    I appreciate your post, but I don't really agree with your logic.

    First of all, the CEO should be concerned first of all about his business; the stock price will follow if the business succeeds.

    Second, if he is concerned about the stock price, then he would still want to enroll as many patients as soon as possible and start them on treatment. Even if a couple of patients don't respond, and the news gets out, the stock price drop can only be temporary until positive results come in. If there are no positive results, then there's nothing to save anyways.

    But I'm not the CEO for a penny-stock biotech company, so I don't know all the ins and outs. And I don't know anyone in that position, and Geert is not giving us all the information he has, and we don't know why. The stock market hates uncertainty, and that's why the price is dropping. I have a thousand shares, and I can afford to sit on them until some results come in.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • he took care most of the businesses.

      phase 3 approved, funding, plant built, some treatment centers approved. A smart CEO knows when treatment should start and how many patients have already enrolled is enough to start treatment at the same time or a couple of days or weeks away are all part of business stategies.

      you said the stock price will follow if the business succeeds. this is not always the case if short sellers drive price down. Isn't this why the SEC created new rules?

 
CVM
0.71-0.01(-1.39%)Jan 30 4:01 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.